Publication at First Faculty of Medicine |
2023
Abstract
Urothelial carcinoma (UC) is the most common urological malignancy. UC may be significantly influenced by immunotherapy.
The platine-based chemotherapy is the cornerstone of first-line therapy of advanced UC, but with a short duration of therapeutic response. The JAVELIN Bladder 100 trial demonstrated the importance of avelumab immunotherapy in patients with metastatic UC without progression on platine-based chemotherapy.
The results of this study demonstrated the significant overall survival prolongation and acceptable toxicity in all patients - and in elderly patients, too, according to recent analysis.